Clostridium difficile diarrhoea in the immunosuppressed patient - Update on prevention and management

Nephrology Dialysis Transplantation

Volumn 19, Issue 10, 2004, Pages 2432-2436

  Schaier, Matthias ^a   Wendt, Constanze ^a   Zeier, Martin ^a   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LEVOFLOXACIN; LINEZOLID; METHOTREXATE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; RIFAMPICIN; TACROLIMUS; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CANCER CHEMOTHERAPY; CLOSTRIDIUM DIFFICILE; DIAGNOSTIC PROCEDURE; DIARRHEA; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RESISTANCE; INFECTION RISK; PERSONAL HYGIENE; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT;

CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 5444261149     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh428     Document Type: Editorial

References (39)

1. Svenungsson B, Burman LG, Jalakas-Pornull K, Lagergren A, Struwe J, Akerlund T. Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. J Clin Microbiol 2003; 41: 4031-4037
2. West M, Pirenne J, Chavers B et al. Clostridium difficile colitis after kidney and kidney - pancreas transplantation. Clin Transplant 1999; 13: 318-323
3. Larson HE, Price AB, Honour P, Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; 1: 1063-1066
4. Barbut F, Petit JC. Epidemiology of Clostridium difficile associated infections. Clin Microbiol Infect 2001; 7: 405-410
5. Bartlett JG. Antibiotic-associated colitis. Dis Mon 1984; 30: 1-54
6. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372
7. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? Arch Surg 2002; 137: 1096-1100
8. Barbut F, Delmee M, Brazier JS et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9: 989-996
9. Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 [Suppl C]: 5-12
10. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-353
11. Komatsu M, Kato H, Aihara M et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003; 22: 525-529
12. Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med 1989; 110: 255-257
13. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26: 1027-1034; quiz 1035-1036
14. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834-844
15. Gerding DN, Johnson S, Peterson LR, Mulligan ME and Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-477
16. Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 1985; 151: 476-481
17. Gopal Rao G, Mahankali Rao CS, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697-701
18. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 [Suppl 2]: ii45-ii53
19. Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50
20. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-245
21. Vaishnavi C, Thapa BR, Thennarasu K, Singh K. Faecal lactoferrin assay as an adjunct to Clostridium difficile diarrhoea. Ind J Pathol Microbiol 2002; 45: 69-73
22. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109-113
23. Cudmore MA, Silva J Jr, Fekety R, Liepman MK, Kim KH. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982; 142: 333-335
24. Blot E, Escande MC, Besson D et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003; 53: 187-92
25. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis 1998; 27: 1540-1541
26. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-354
27. Frost F, Craun GF, Calderon RL. Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. Emerg Infect Dis 1998; 4: 619-625
28. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210
29. Rutala WA, Gergen MF, Weber DJ. Inactivation of Clostridium difficile spores by disinfectants. Infect Control Hosp Epidemiol 1993; 14: 36-39
30. Wullt M, Odenholt I, Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect Control Hosp Epidemiol 2003; 24: 765-768
31. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection - relapse or reinfection? J Hosp Infect 1998; 38: 93-100
32. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115: 543-546
33. Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995; 169: 480-483
34. Anderson TL, McGregor A. Evaluation of the clearview Clostridium difficile toxin A test and various selective culture media in comparison with the cytotoxin assay for the diagnosis of Clostridium difficile-associated diarrhoea. Pathology 2003; 35: 244-247
35. Probert CS, Jones PR, Ratcliffe NM. A novel method for rapidly diagnosing the causes of diarrhoea. Gut 2004; 53: 58-61
36. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-868
37. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981-988
38. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994; 271: 1913-1918
39. Riquelme AJ, Calvo, MA, Guzman AM et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41-43